Archive · 3 Oct 2026
Aurobindo Pharma Acquires US Research Firm for ₹127.32 Crore
Aurobindo Pharma has bought a US company called A1 Biochem Labs LLC.
It paid USD 15.247 million, or about ₹127.32 crore.
The deal was completed on October 2, 2026.
A1 Labs helps drug and biotechnology companies with research and chemistry work.
It will become a step-down subsidiary of A1 Labs India.
A1 Labs reported lower sales in 2025 than in 2024.
Aurobindo says the purchase will help it expand its work across the medicines ingredients business.
It also expects to build a dedicated research, development and manufacturing platform.
Aurobindo Pharma acquired A1 Biochem Labs LLC for USD 15.247 million, approximately ₹127.32 crore.
The acquisition was completed on October 2, 2026, and A1 Labs LLC will become a step-down subsidiary of A1 Labs India.
Based in Wilmington, North Carolina, A1 Labs LLC provides contract research and chemistry services to pharmaceutical and biotechnology companies.
A1 Labs LLC reported sales of USD 9.23 million in 2024 and USD 5.92 million in 2025.
Aurobindo said the deal supports its API business lifecycle expansion and plans for a dedicated CRDMO platform.
- Who
- Aurobindo Pharma acquired A1 Biochem Labs LLC from Rajendra Gadikota.
- What
- The acquisition was for USD 15.247 million, approximately ₹127.32 crore; A1 Labs LLC will become a step-down subsidiary of A1 Labs India.
- When
- The acquisition was completed on October 2, 2026, and announced on Thursday.
- Where
- A1 Labs LLC is based in Wilmington, North Carolina, USA.
- Why
- Aurobindo said the acquisition supports expansion across the API business lifecycle and the creation of a dedicated CRDMO platform.
- Purchase price
- USD 15.247 million, approximately ₹127.32 crore
- Completion date
- October 2, 2026
- A1 Labs location
- Wilmington, North Carolina, USA
- 2024 sales
- USD 9.23 million
- 2025 sales
- USD 5.92 million
- Business
- Contract research and chemistry services, including custom synthesis and medicinal chemistry
- Regulatory approvals
- The acquisition is not subject to governmental or regulatory approvals
- Related-party status
- The acquisition by A1 USA Inc is considered a related party transaction; A1 Labs LLC was acquired from Rajendra Gadikota, a director of A1 Labs India